AChE Blocking Peptide, Blocking Peptides
- Known as:
- AChE Blocking Peptide, Blocking Peptides
- Catalog number:
- 33R-9575
- Product Quantity:
- 100 ug
- Category:
- -
- Supplier:
- Fitzgerald
- Gene target:
- AChE Blocking Peptide Peptides
Related genes to: AChE Blocking Peptide, Blocking Peptides
- Gene:
- ACHE NIH gene
- Name:
- acetylcholinesterase (Cartwright blood group)
- Previous symbol:
- YT
- Synonyms:
- -
- Chromosome:
- 7q22.1
- Locus Type:
- gene with protein product
- Date approved:
- 1989-06-02
- Date modifiied:
- 2019-04-23
Related products to: AChE Blocking Peptide, Blocking Peptides
Related articles to: AChE Blocking Peptide, Blocking Peptides
- The delta opioid receptor (DOR) has been a focus of research for the treatment of depression and certain pain disorders. Unfortunately, clinical translation of delta opioid agonists to humans has proved challenging partly because of their propensity to cause convulsions at higher doses. The discovery that the DOR can be allosterically modulated has opened the possibility of developing compounds that may be able to produce some of the positive therapeutic effects, either as standalone treatments to enhance the action of endogenous opioid peptides or as sparing agents allowing the use of lower doses of DOR agonists, which could reduce the chance of inducing convulsions. BMS-986187 is a positive allosteric modulator of DOR. The behavioral effects of BMS-986187 related to depression and pain have not been investigated. In this study, we examined the impact of BMS-986187 on DOR-mediated antidepressant-like effects in the forced swim test, antinociceptive and antiallodynic actions and propensity to cause convulsions. BMS-986187 (1 mg/kg) showed antidepressant-like effects when administered alone, but did not produce convulsions. BMS-986187 (10 mg/kg) also enhanced the antinociceptive and antiallodynic effects of the standard DOR agonist SNC80, with only a very minor effect on SNC80-mediated convulsions. The results suggest the development of positive modulators of DOR for the management of pain and/or depression. SIGNIFICANCE STATEMENT: The delta opioid receptor (DOR) has been suggested as a target to treat depression and pain. However, agonists at this receptor can cause convulsions. This study demonstrates that a positive allosteric modulator of DOR administered alone reduces depression-like behaviors and, in combination with a DOR agonist, shows robust pain-relieving actions, without convulsive effects. This suggests a novel and safe treatment for depression and/or pain. - Source: PubMed
Publication date: 2026/05/14
Jutkiewicz Emily MPalleiko Benjamin ADripps Isaac JLivingston Kathryn ERoques Bernard PClements Benjamin MTraynor John R - Arthritis is a collective term for joint disorders, which are characterised by inflammation, pain, stiffness in joints and can progressively lead to disabilities. It is a worldwide problem affecting millions of people. The two most prevalent forms of inflammatory disease include rheumatoid arthritis and osteoarthritis, based on the disease etiology, pathogenesis and clinical therapy. Symptoms like pain in the joint, stiffness, redness, and swelling are most often seen in this case. This review emphasises the current idea about arthritis, highlighting therapeutic interventions including key herbal remedies and their marketed formulations, and synthetic drugs. Also, we discuss about emerging trends and future directions aimed at enhancing patient outcomes through personalized medication, biotechnology, and integrative approaches. - Source: PubMed
Publication date: 2026/06/06
Sahu GuptanjaliBadhei LipanjaliNanda AshirbadKanhar SatishSahoo Biswa MohanMishra Kirtimaya - Prehabilitation is an emerging preoperative strategy designed to optimise patients' functional capacity before surgery to improve postoperative outcomes. Previous studies have demonstrated its clinical benefit, including enhanced recovery and reduced postoperative complications. However, the mechanisms underlying these benefits remain poorly understood. This exploratory study investigates the potential effects of prehabilitation on pre- and postoperative immune function. - Source: PubMed
Publication date: 2026/06/06
Jacobs Lotte M CDrager Luuk Dvan Eijk Lucas THelder Leonie SJoosten Leo A BStrijker Dieuwkevan Laarhoven Cornelis J H Mvan den Heuvel BaukjeWarlé Michiel C - Psychological flexibility, the capacity to remain open to difficult internal experiences while engaging in values-based action, has been linked to better mental health after spinal cord injury (SCI). Yet how these processes are enacted in daily life is underexplored. This study qualitatively examined lived experiences of psychological flexibility and its processes among adults with SCI. - Source: PubMed
Publication date: 2026/06/06
Han AreumJenkins Jeremy - Fibromyalgia syndrome (FMS) and major depressive disorder (MDD) frequently co-occur together, but the mechanisms linking these conditions remain poorly understood. This study aimed to delineate symptom clusters within the FMS-MDD network, identify bridging symptoms connecting these clusters, and evaluate the integrative role of pain severity. - Source: PubMed
Publication date: 2026/06/06
Reichert JulianDrusko ArminBeiner EvaHermes MichellePapaioannou VassiliosHäuser WinfriedEich WolfgangTesarz Jonas